WANBURY
|
|
BOM : 524212     NSE : WANBURY     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Jun 29,2022 |
Price(EOD): ₹ 67.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 221.54 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
WANBURY | 13% | -0.4% | -30.4% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | -2.6% | 23.2% |
DIVIS LABORATORIES | -2.2% | -0.2% | -14.5% |
DR REDDYS LABORATORIES | 1.6% | -0.1% | -17.5% |
CIPLA | 1.4% | -4.9% | -1.2% |
GLAND PHARMA | 1.7% | -7.3% | -17.1% |
PIRAMAL ENTERPRISES | 2.1% | -12.2% | -30.3% |
CADILA HEALTHCARE | 2.9% | -5.9% | -42.7% |
TORRENT PHARMACEUTICALS | -0.5% | -0.3% | -0.1% |
FUNDAMENTAL ANALYSIS OF WANBURY
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF WANBURY
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
-
P/E Calculated based on EPS of -5.04
[ Mar2021 - Consolidated Results ] -
P/B Calculated based on Book Value of -62.6
[ Mar2021 - Consolidated Results ] 0.43
P/S Calculated based on Revenues of 511.186 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 48% 141% |
SHARE PRICE MOMENTUM OF WANBURY
WANBURY vs SENSEX
DEBT OF WANBURY
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
-0.99 -1.39 -1.27 -1.22 |
-0.83 -1.14 -1.11 -1.03 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF WANBURY
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF WANBURY
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
7.66% 44.95% 19066.1% 22030% |
11.58% 824.77% 1018.6% 1021.78% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
WANBURY related INDICES
You may also like the below Video Courses
FAQ about WANBURY
Is WANBURY good for long term investment?
As on Jun 29,2022, the Fundamentals of WANBURY look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of WANBURY . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is WANBURY UnderValued or OverValued?
As on Jun 29,2022, WANBURY is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of WANBURY ?
As on Jun 29,2022, the Intrinsic Value of WANBURY is Rs. 36.95 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -96.42
Fair Value [Median EV / Sales Model] : Rs. 45.76
Fair Value [Median Price / Sales Model] : Rs. 28.14
Median Fair Value of WANBURY : Rs. 36.95
Is WANBURY trading at a Premium or Discount?
As on Jun 29,2022, WANBURY is trading at a Premium of 83% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
